Aquyre Biosciences

Founded with the mission to revolutionize tissue assessment, Aquyre Biosciences leverages proprietary technologies to provide non-invasive, non-destructive, intraprocedural tissue adequacy assessments. Their core product combines Full-Field Optical Coherence Tomography (FFOCT) and other imaging techniques to deliver high-resolution, 3D imaging of tissue micro-architecture within two minutes. This rapid and precise assessment aids medical professionals in identifying various cell types, including cancer cells, thus enhancing biopsy sample evaluation. The company primarily focuses on the healthcare market, particularly in areas requiring quick and accurate tissue diagnostics.

Notable affiliated individuals include Dr. Wilson Tsai, Director of the Thoracic Program at John Muir Health, who supports the clinical applications of Aquyre's technology. The company has garnered attention for its significant contributions to lung biopsy procedures, becoming an industry leader in this niche. By enabling quicker and more accurate tissue assessments, Aquyre Biosciences has made a substantial impact on pathology workflows and patient outcomes, helping prioritize specimens for further examination and improving diagnostic accuracy.